ak101
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jan 9, 2018 (NCT04172233)
Timeline
Indications
Mechanism of action
- Interleukin-23 subunit alphaINHIBITOR
IL23A inhibitor
- Interleukin-12 subunit betaINHIBITOR
IL12B inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05509361 | Phase 3 | Apr 8, 2022 | Akeso Pharmaceuticals, Inc. |
| NCT05120297 | Phase 3 | Nov 1, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT06281704 | Phase 1 | Nov 26, 2020 | Akeso Pharmaceuticals, Inc. |
| NCT04173637 | Phase 2 | Nov 30, 2019 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences, Peking University |
| NCT04172233 | Phase 1/Phase 2 (Phase 2) | Jan 9, 2018 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 5 | 5 | 3 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1